Company profile for PulseSight Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

PulseSight Therapeutics is actively progressing a promising pipeline of novel non-viral minimally-invasive gene therapies. The company's focus is on addressing the unmet needs for treating severe retinal diseases that can lead to blindness. PulseSight Therapeutics specifically targets conditions such as age-related macular degeneration (AMD), including wet AMD and late-stage dry AMD or Geographic atrophy (GA). The development ...
PulseSight Therapeutics is actively progressing a promising pipeline of novel non-viral minimally-invasive gene therapies. The company's focus is on addressing the unmet needs for treating severe retinal diseases that can lead to blindness. PulseSight Therapeutics specifically targets conditions such as age-related macular degeneration (AMD), including wet AMD and late-stage dry AMD or Geographic atrophy (GA). The development of these gene therapies aims to provide innovative and effective solutions for severe retinal diseases that currently lack satisfactory treatments.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
11 Rue Watt Bat B, 75013, Paris
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/14/3165902/0/en/Peer-Reviewed-Publication-Provides-Evidence-for-Iron-Dysregulation-as-a-Driver-of-Dry-AMD-GA-and-the-Potential-of-Transferrin-to-Restore-Iron-Balance-Reinforcing-PulseSight-s-Thera.html

GLOBENEWSWIRE
14 Oct 2025

https://www.globenewswire.com/news-release/2025/07/07/3110761/0/en/First-patient-dosed-in-the-Phase-I-clinical-trial-of-PulseSight-Therapeutics-PST-611-treatment-for-dry-AMD-Geographic-Atrophy.html

GLOBENEWSWIRE
07 Jul 2025

https://www.globenewswire.com/news-release/2025/02/13/3025626/0/en/PulseSight-Therapeutics-Announces-First-Close-of-its-Series-A-Financing-to-Fund-Clinical-Development-of-PST-611-in-dry-AMD.html

GLOBENEWSWIRE
13 Feb 2025

https://www.globenewswire.com/news-release/2025/01/14/3009029/0/en/PulseSight-Therapeutics-announces-the-initiation-of-the-clinical-plan-of-PST-611-Transferrin-Vectorized-Therapy-for-dry-AMD-Geographic-Atrophy.html

GLOBENEWSWIRE
14 Jan 2025

https://www.globenewswire.com/news-release/2024/11/06/2975431/0/en/PulseSight-Therapeutics-Presents-New-Data-on-PST-611-Transferrin-Vectorized-Therapy-for-Geographic-Atrophy-at-EVER-Congress-2024.html

GLOBENEWSWIRE
06 Nov 2024

https://www.globenewswire.com/news-release/2024/10/07/2958670/0/en/PulseSight-Therapeutics-to-Present-Data-on-PST-611-at-EVER-Congress-2024.html

GLOBENEWSWIRE
07 Oct 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty